PRESS RELEASE published on 06/25/2024 at 17:45, 2 years 4 months ago Newron Pharmaceuticals reports on its 2024 Investor Day in New York City Newron Pharmaceuticals reports on its 2024 Investor Day in New York City, highlighting evenamide's potential in treating treatment-resistant schizophrenia. Leading experts present clinical data and benefits of evenamide Clinical Data Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide
BRIEF published on 06/18/2024 at 17:50, 2 years 5 months ago Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City Investor Day Clinical Research Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF published on 06/18/2024 at 17:50, 2 years 5 months ago Journée des investisseurs 2024 de Newron Pharmaceuticals, le 25 juin 2024, à New York Schizophrénie Produits Pharmaceutiques Newron Evenamide Recherche Clinique Journée Des Investisseurs
PRESS RELEASE published on 06/18/2024 at 17:45, 2 years 5 months ago Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City. Key opinion leaders to review findings on evenamide program for treatment-resistant schizophrenia Investor Day Neuroscience Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF published on 06/05/2024 at 17:50, 2 years 5 months ago Newron Pharmaceuticals to Host 2024 Investor Day in New York City Investor Day New York City Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF published on 06/05/2024 at 17:50, 2 years 5 months ago Newron Pharmaceuticals organisera la journée des investisseurs 2024 à New York Schizophrénie Produits Pharmaceutiques Newron Evenamide Journée Des Investisseurs La Ville De New York
PRESS RELEASE published on 06/05/2024 at 17:45, 2 years 5 months ago Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City Newron Pharmaceuticals announces 2024 Investor Day in New York City focusing on evenamide for treatment-resistant schizophrenia. Leading experts to present new findings Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide Neurobiology
BRIEF published on 05/13/2024 at 07:05, 2 years 6 months ago Newron Pharmaceuticals Announces Positive Results for Evenamide in Schizophrenia Study Clinical Study Schizophrenia Newron Pharmaceuticals Evenamide Mental Health Treatment
BRIEF published on 05/13/2024 at 07:05, 2 years 6 months ago Newron Pharmaceuticals annonce des résultats positifs pour l'Evenamide dans une étude sur la schizophrénie Schizophrénie Étude Clinique Produits Pharmaceutiques Newron Evenamide Traitement De Santé Mentale
PRESS RELEASE published on 05/13/2024 at 07:00, 2 years 6 months ago Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients Newron Pharmaceuticals S.p.A. presents compelling additional data from study 008A showcasing the efficacy of evenamide in poorly responding schizophrenia patients. Significant multi-domain benefits observed in PANSS and CGI-C ratings Clinical Trial Study Results Newron Pharmaceuticals Evenamide Schizophrenia Patients
Published on 11/20/2026 at 15:00, 1 day 23 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 2 days ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 13:30, 2 days 1 hour ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 2 days 1 hour ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 15 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 22:39, 1 day 16 hours ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 1 day 17 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 1 day 18 hours ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 1 day 20 hours ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 1 day 20 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 21 hours ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 1 day 21 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 19 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR